Showing 4861-4870 of 5646 results for "".
- DORC Launches New Range of EVA EquiPhaco Needles and Sleeveshttps://modernod.com/news/dorc-launches-new-range-of-eva-equiphaco-needles-and-sleeves/2477940/DORC announced the launch of a new range of EVA EquiPhaco needles and sleeves, which are designed to deliver superior ultrasound efficiency, improved anterior chamber stability, and easier sleeve positioning. T
- 2021 ASCRS Annual Meeting Pushed Back to Augusthttps://modernod.com/news/2021-ascrs-annual-meeting-pushed-back-to-august/2477939/ASCRS announced that it is pushing back its 2021 annual meeting in San Francisco from April to August. “This decision was thoroughly researched and discussed, and when weighed against the risks of possibly losing another meeting to the coronavirus, we felt we had no other alternative
- Visual Clinic’s Patient Flow Management Solution Aims to Help Eye Care Clinics Operate Post-COVID-19https://modernod.com/news/visual-clinics-patient-flow-management-solution-aims-to-help-eye-care-clinics-operate-post-covid-19/2477935/Visual Clinic is offering a solution designed to help eye care clinics achieve better patient flow. The software aims to help practices run at peak efficiency, improve the patient experience, maximize practice resources, and keep overhead costs low while optimizing revenue. Additionally
- CDC Broadens Guidance on Americans Facing Risk of Severe COVID-19https://modernod.com/news/cdc-broadens-guidance-on-americans-facing-risk-of-severe-covid-19/2477936/The Centers for Disease Control and Prevention on Thursday broadened its warning about who is at risk of developing severe disease from COVID-19 infection, suggesting even younger people who are obese or have other health conditions can become seriously ill if they contract the virus, according t
- AMA Pushes for Federal Intervention to Reform Prior Authorizationhttps://modernod.com/news/ama-pushes-for-federal-intervention-to-reform-prior-authorization/2477934/Docs say health plans have made little progress toward streamlining prior authorization—despite pledging to do so 2 years ago, according to a FierceHealthcare report.
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r
- Sanofi Sees Potential Approval of COVID-19 Vaccine in First Half of 2021https://modernod.com/news/sanofi-sees-potential-approval-of-covid-19-vaccine-in-first-half-of-2021/2477923/Sanofi said Tuesday that it expects potential approval of a COVID-19 vaccine being jointly developed with GlaxoSmithKline in the first half of next year, brought forward from an earlier estimate of the second half of 2021. A phase 1/2 study of the recombinant protein-based vaccine approach, whic
- How Regeneron’s COVID-19 Antibody Cocktail Cuts the Risk of Resistancehttps://modernod.com/news/how-regenerons-covid-19-antibody-cocktail-cuts-the-risk-of-resistance/2477920/When Regeneron said in March that it would speed an antibody treatment into clinical trials for COVID-19, its scientists insisted a cocktail of two antibodies would be more effective than one alone. Now they’re explaining why they chose the two antibodies that moved into human trials last w
- UK to Test Weekly, Swabless COVID-19 Screening for Health Care Workers, Students and Morehttps://modernod.com/news/uk-to-test-weekly-swabless-covid-19-screening-for-health-care-workers-students-and-more/2477918/The UK government will begin testing a new, swabless coronavirus test, designed to be completed at home on a weekly basis by spitting into a collection tube, according to a FierceBiotech
- Viela Bio Announces FDA Approval of Uplinza (Inebilizumab) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)https://modernod.com/news/viela-bio-announces-fda-approval-of-uplinza-inebilizumab-for-the-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd/2477912/Viela Bio announced the FDA approval of Uplizna (inebilizumab-cdon) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). The monotherapy drug is the first and only B cell-depleting antibody approved for the disease. Uplizna is indicated for those who are